Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Abexinostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Abexinostat (PCI-24781) is under development for the treatment of metastatic renal cell carcinoma, follicular lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, relapsed and refractory mantle cell lymphoma, solid tumor, breast cancer, epithelial ovarian cancer, metastatic urothelial tract cancer, metastatic melanoma, non-small cell lung cancer, head and neck cancer squamous cell carcinoma, recurrent high grade glioma, glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma and medullary thyroid cancer. It is formulated as a capsule and is administered through oral route. It acts by targeting histone deacetylase (HDAC). It was also under development for the treatment of lung cancer, colon cancer, gastric cancer, metastatic colorectal cancer, pancreatic cancer, nasopharyngeal cancer, haematological malignancies such as follicular non-Hodgkin lymphoma, and chronic lymphocytic leukemia (CLL) as second line of therapy, refractory and relapsed multiple myeloma as first and second line of therapy, refractory and relapsed acute myeloid leukemia, acute lymphoblastic leukemia, high or intermediary-2 risk myelodysplastic syndrome and sarcomas as second line of therapy, fallopian tube cancer, peritoneal cancer, brain tumor and neuroblastoma.
Xynomic Pharmaceuticals overview
Xynomic Pharmaceuticals (Xynomic Pharmaceuticals Holdings) develops and sells innovative small molecule drugs for the treatment of cancer across various patients. The company is headquartered in Shanghai, China.
For a complete picture of Abexinostat’s drug-specific PTSR and LoA scores, buy the report here.